All Comparisons
AOD-9604 vs Tesamorelin
Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.
AOD-9604: CTesamorelin: A
| Attribute | AOD-9604 | Tesamorelin |
|---|---|---|
| Category | Metabolic / Fat Loss | Growth Hormone Secretagogue |
| Evidence Rating | C — Phase I–II Clinical Trials | A — FDA Approved |
| Clinical Status | Clinical development discontinued after Phase 2; GRAS status for food use | FDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy |
| Mechanism | AOD-9604 (C78H123N23O23S2) works through a dual-action mechanism: it accelerates breakdown of stored fat (lipolysis) via cAMP signaling and enzymatic activation (stimulating hormone-sensitive lipase), while simultaneously blocking formation of new fat (lipogenesis). It stimulates lipolysis in a mann... | Tesamorelin binds to and stimulates human GRF (growth hormone-releasing factor) receptors on the anterior pituitary with similar potency as endogenous GRF, stimulating synthesis and release of endogenous growth hormone. This increases IGF-1 and IGFBP-3 levels, leading to increased lipolysis and redu... |
| Half-Life | ~30 minutes | ~26–38 minutes |
| Bioavailability | — | — |
| Molecular Weight | ~1815.1 g/mol | ~5135.9 g/mol |
| WADA Status | Prohibited | Prohibited |
| Research Half-Life | ~30 minutes | ~26–38 minutes |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | Not FDA-approved as a drug. FDA granted GRAS status for food use (2014). Available as research chemical. | FDA-approved: Egrifta SV (Oct 2019) and Egrifta WR (March 2025) for HIV-associated lipodystrophy. Prescription only. |
Research Material Specifications
Catalog specifications for the corresponding research materials, including batch documentation coverage.
| Specification | AOD-9604 | Tesamorelin |
|---|---|---|
| Purity Standard | ≥98% | ≥98% |
| CAS Number | 221231-10-3 | 218949-48-5 |
| Molecular Formula | N/A | C₂₂₃H₃₇₀N₇₂O₆₉S |
| Available Formats | 10mg | 10mg, 20mg, 10mg |
| Batch COAs Published | — | — |
| Stock Status | Out of stock | In stock |
Availability at Volta Peptides
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.